Compare Bristol-Myers Squibb Co (BMY) vs Nokia Corp (NOK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Nokia Corp — how do they compare? Bristol-Myers Squibb Co trades at $58.45 (market cap $116.30B), while Nokia Corp trades at $10.97 (market cap $65.32B). The key difference: Bristol-Myers Squibb Co is the larger of the two by market cap, and Bristol-Myers Squibb Co pays the higher dividend (4.42%). Which is the better fit depends on your goals.
| BMY | NOK | |
|---|---|---|
Market Cap | $116.30B | $65.32B |
Sector | Health | Technology |
52-Week High | $62.37 | $16.83 |
52-Week Low | $42.60 | $4.05 |
Enterprise Value | $152.24B | $62.14B |
Dividend Yield | 4.42% | 1.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
Nokia (NOK) trades at $11.675, down 6.04% today amid a broader technical pullback despite strong AI-driven momentum. The stock has surged over 100% YTD on AI infrastructure partnerships, including a $1 billion deal with Nvidia. Recent earnings show mixed results with Q1 2026 missing expectations, but Q3 and Q4 2025 beat estimates. Valuation metrics appear elevated with a P/E of 73.32, while profitability remains modest with a 3.98% net margin. Cash flow trends show volatility, with 2025 net cash flow negative at -$1.16 billion.
Nokia's AI transformation presents significant upside potential with analyst consensus target of $18.00 (54% upside), but high valuation and execution risks warrant caution. The company's pivot to AI networking infrastructure is gaining traction, though supply constraints and heavy R&D spending could pressure near-term profitability. Technical indicators suggest near-term bearish pressure with key support at $11.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Nokia Corp
Nokia is a leading vendor in the telecommunications equipment industry. The company's network business derives revenue from selling wireless and fixed-line hardware, software, and services. Nokia's technology segment licenses its patent portfolio to handset manufacturers and makes royalties from Nokia-branded cellphones. The company, headquartered in Espoo, Finland, operates on a global scale, with most of its revenue from communication service providers.
Read more on NOK →
